Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMRI's 30-Y Financials

Financials (Next Earnings Date: 2018-05-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

AMRI Guru Trades in Q4 2016

Jim Simons 357,900 sh (+3.07%)
Chuck Royce 1,290,911 sh (+2.92%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 80,589 sh (-48.93%)
» More
Q1 2017

AMRI Guru Trades in Q1 2017

Paul Tudor Jones 16,300 sh (New)
Ken Fisher 144,417 sh (+79.20%)
Chuck Royce 1,518,276 sh (+17.61%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 148,342 sh (-58.55%)
» More
Q2 2017

AMRI Guru Trades in Q2 2017

Mario Gabelli 162,073 sh (New)
John Paulson 314,200 sh (New)
Jim Simons 295,542 sh (+99.23%)
Ken Fisher 184,589 sh (+27.82%)
Murray Stahl 56,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 396,275 sh (-73.90%)
» More
Q3 2017

AMRI Guru Trades in Q3 2017

John Paulson Sold Out
Mario Gabelli Sold Out
Ken Fisher Sold Out
Jim Simons Sold Out
Chuck Royce Sold Out
Murray Stahl Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-09-30 Sold Out 0.01%$21.62 - $21.76 $ 21.740%0
Mario Gabelli 2017-09-30 Sold Out 0.02%$21.62 - $21.76 $ 21.740%0
John Paulson 2017-09-30 Sold Out 0.09%$21.62 - $21.76 $ 21.740%0
John Paulson 2017-06-30 New Buy0.09%$13.37 - $21.72 $ 21.7420%314,200
Ken Fisher 2017-06-30 Add 27.82%$13.37 - $21.72 $ 21.7421%184,589
Mario Gabelli 2017-06-30 New Buy0.02%$13.37 - $21.72 $ 21.7421%162,073
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:NAS:ATNX, NAS:MRTX, SZSE:000518, SHSE:603896, NAS:RGNX, HKSE:01681, SAU:2070, SZSE:300149, NAS:GERN, NYSE:BHVN, SZSE:300255, NAS:AMRN, SZSE:002872, XPAR:GNFT, XKRX:102940, SZSE:300204, NAS:NTLA, HKSE:06826, XKRX:078160, SZSE:300147 » details
Traded in other countries:AYM.Germany,
Headquarter Location:USA
Albany Molecular Research Inc is a contract research and manufacturing company, providing customers drug discovery, development and manufacturing services.

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Top Ranked Articles about Albany Molecular Research Inc

3ST Research Files Litigation Alleging Fraud and Conversion of Inventor's Intellectual Property Rights by Albany Molecular Research Inc. (AMRI)
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR
Control4 Set to Join S&P SmallCap 600
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Albany Molecular Research, Inc. – AMRI
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)
WeissLaw LLP: The Proposed Acquisition of Albany Molecular Research Inc. May Not Be In the Best Interest of AMRI Shareholders
Harwood Feffer LLP Announces Investigation of Albany Molecular Research, Inc.
ALBANY MOLECULAR INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albany Molecular Research, Inc.
Albany Molecular (AMRI) Alert: J&W Investigates Price and Process of Proposed Sale of Albany Molecular Research, Inc.; Is $21.75 a Fair Price?
AMRI Signs Definitive Agreement To Be Acquired By The Carlyle Group and GTCR for $21.75 per share in cash

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $680.81
EPS (TTM) $ -1.41
52-Week Range $13.01 - 22.17
Shares Outstanding (Mil)43.12

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 722 780
EBIT (Mil $)
EBITDA (Mil $) 144 162
EPS ($) 1.12 1.50
EPS without NRI ($) 1.12 1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}